# AcceleRET-Lung: HCP commentary report

> 70 verified statements (11 from clinicians verified by NPI or staff page) from 30 commentary sources · 6 findings · updated Oct 28, 2026

## Report

- Trial: A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
- NCT ID: NCT04222972
- Registry: https://clinicaltrials.gov/study/NCT04222972
- Sponsor: Hoffmann-La Roche
- Phase: Phase 3
- Status: Terminated
- Drugs: carboplatin, cisplatin, pemetrexed, pembrolizumab, gemcitabine, paclitaxel, nab-paclitaxel
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: 7495d418f81528cc7e06fefc10d46e2be72e19c53218e511e0e6fa0f958143a4

## Counts

- HCP commentary sources screened: 53
- Sources cited by verified statements: 32
- Verified statements: 70
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 11
- Findings: 6
- People found in screened sources: 14
- People identity-verified: 11
- Voices cited: 14
- Organisational or shared accounts (not counted as people): 5

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on AcceleRET-Lung in the sources reviewed for this edition leads to one open question: How should Medical Affairs explain the favorable frontline disease-control interpretation while preserving the uncertainty around infection-risk mitigation, survival benefit and accessible treatment choice? Its leading findings: (1) infection-risk mitigation is the most consequential unresolved qualification. (2) favorable frontline positioning rests on disease control, with safety and survival caveats. (3) premature closure and immature OS constrain the evidentiary conclusion. 3 more findings follow. 53 sources screened, 32 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

How should Medical Affairs explain the favorable frontline disease-control interpretation while preserving the uncertainty around infection-risk mitigation, survival benefit and accessible treatment choice?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Infection-risk mitigation is the most consequential unresolved qualification
- F2. Favorable frontline positioning rests on disease control, with safety and survival caveats
- F3. Premature closure and immature OS constrain the evidentiary conclusion
- F4. Subgroup reassurance is clinically useful but does not erase eligibility boundaries
- F5. Molecular testing is framed as part of the frontline treatment decision
- F6. Choice among RET inhibitors raises differentiation and European access questions

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 19 | 17 | 14 | 8 | recorded | 3 |
| F2 | 21 | 17 | 16 | 8 | recorded | 3 |
| F3 | 17 | 17 | 8 | 5 | none recorded | 3 |
| F4 | 9 | 7 | 5 | 4 | none recorded | 3 |
| F5 | 5 | 5 | 5 | 3 | none recorded | 2 |
| F6 | 7 | 6 | 5 | 2 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 1 | 0 | 0 | 12 | 22 | 2 | 12 posts and articles, 1 podcast or video, 1 registry | yes |
| F2 | 12 | 0 | 0 | 1 | 8 | 27 | 1 | 15 posts and articles, 1 podcast or video | yes |
| F3 | 4 | 0 | 0 | 0 | 13 | 20 | 0 | 5 posts and articles, 1 podcast or video, 1 publication, 1 registry | yes |
| F4 | 2 | 0 | 0 | 1 | 6 | 10 | 0 | 3 posts and articles, 1 podcast or video, 1 registry | yes |
| F5 | 3 | 0 | 0 | 0 | 2 | 6 | 0 | 4 posts and articles, 1 registry | yes |
| F6 | 1 | 1 | 0 | 2 | 3 | 7 | 0 | 4 posts and articles, 1 registry | yes |

### Trial dimensions

- Primary endpoint: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS): F1 (4 shared claims), F2 (12 shared claims), F3 (4 shared claims), F4 (4 shared claims), F6 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims), F2 (10 shared claims), F3 (4 shared claims), F4 (2 shared claims), F6 (1 shared claims)
- Population and setting: F2 (1 shared claims), F3 (2 shared claims), F4 (5 shared claims)
- The comparison: F2 (3 shared claims), F3 (6 shared claims), F4 (4 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (18 shared claims), F2 (13 shared claims), F3 (3 shared claims), F4 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Design and conduct: F2 (3 shared claims), F3 (9 shared claims), F4 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 70 | Paid |
| Trial aspects mapped | 9 | Free |
| Sources with links | 32 | Counts free |
| Speaker attribution for cited voices | 14 | Paid |

## Trial aspects

9 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) | discussed | 20 | 17 |
| Secondary endpoints | discussed | 15 | 12 |
| Population and setting | discussed | 7 | 4 |
| The comparison | discussed | 11 | 11 |
| Safety and tolerability | discussed | 30 | 22 |
| Design and conduct | discussed | 10 | 7 |
| Molecular testing before the frontline decision | discussed | 4 | 4 |
| Alternative selective RET inhibitors and future differentiation | discussed | 4 | 3 |
| European access and treatment continuity | discussed | 2 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 50 | 29 |
| Bluesky threads | 2 | 0 |
| YouTube | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2020-01-09 to 2026-09-11
- Cited window: 2024-02-03 to 2026-09-11
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
- Registry: NCT04222972 (https://clinicaltrials.gov/study/NCT04222972)
- Study IDs: BO42864 · 2019-002463-10 · BLU-667-2303 (CT.Gov) · 2023-505035-12-00 (EU CT number)
- Sponsor: Hoffmann-La Roche
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Terminated
- Enrollment: 223 (actual)
- Start: 2020-07-24 (actual)
- Primary completion: 2025-01-27 (actual)
- Primary endpoint: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months)
- Intervention: Pralsetinib (drug)
- Intervention: Carboplatin (drug)
- Intervention: Cisplatin (drug)
- Intervention: Pemetrexed (drug)
- Intervention: Pembrolizumab (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Paclitaxel (drug)
- Intervention: Nab-Paclitaxel (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on sponsor termination and accrual completeness when interpreting first-line pralsetinib evidence.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Repeated summaries and reposts cannot be counted as independent clinical agreement.
- Discussion that did not clearly name the trial or used different spellings may be missing. Two passages were not fully assessed, so additional relevant views may be absent.
- Only part of the available regulatory material was examined; the safety-alert relays are not a complete assessment of current labeling or all regulatory communications.
- No primary publication of the randomized AcceleRET-Lung results is included. The reviewed publication concerns ARROW, a distinct single-arm phase I/II study.
- Enrollment descriptions and termination timing differ across sources and have not been reconciled. Source-specific descriptions should not be silently standardized.
- Post-amendment infection observations do not establish a causal reduction in mortality or prove that risk was eliminated; trial patients and the separate safety databases must remain distinct.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The sources do not provide a head-to-head ranking of selective RET inhibitors, specific toxicity differences for every alternative, or country-level European access criteria.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition

Last checked for new commentary 2026-10-28. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (70 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/acceleret-lung-nct04222972
- Agents: POST https://www.erudio.com/api/orders with {"report": "acceleret-lung-nct04222972", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=acceleret-lung-04222972

## Cite

Erudio Health. AcceleRET-Lung (NCT04222972): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/acceleret-lung-nct04222972

## Machine access

- JSON: https://www.erudio.com/reports/acceleret-lung-nct04222972.json
- Markdown: https://www.erudio.com/reports/acceleret-lung-nct04222972.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "acceleret-lung-04222972"}`